PubMed

Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.

Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP.

Clin Cancer Res. 2009 Nov 15;15(22):7099-105. Epub 2009 Nov 3.PMID: 19887483 [PubMed - in process]Related articles

Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone.

Sartor O, Nakabayashi M, Taplin ME, Ross RW, Kantoff PW, Balk SP, Oh WK.

Clin Genitourin Cancer. 2009 Oct;7(3):E90-2.PMID: 19815488 [PubMed - in process]Related articles

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.

Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, Eymard JC, Falcon S, Calabrò F, James N, Bodrogi I, Harper P, Wirth M, Berry W, Petrone ME, McKearn TJ, Noursalehi M, George M, Rozencweig M.

J Clin Oncol. 2009 Nov 10;27(32):5431-8. Epub 2009 Oct 5.PMID: 19805692 [PubMed - in process]Related articles

Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.

Sartor O, Gomella LG, Gagnier P, Melich K, Dann R.

Can J Urol. 2009 Oct;16(5):4806-12.PMID: 19796455 [PubMed - indexed for MEDLINE]Related articles

New therapeutic agents for castration-refractory prostate cancer.

Patten DY, Sartor O.

Clin Genitourin Cancer. 2009 Aug;7(2):E4-6. No abstract available. PMID: 19692323 [PubMed - in process]Related articlesFree article

Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?

Richey EA, Lyons EA, Nebeker JR, Shankaran V, McKoy JM, Luu TH, Nonzee N, Trifilio S, Sartor O, Benson AB 3rd, Carson KR, Edwards BJ, Gilchrist-Scott D, Kuzel TM, Raisch DW, Tallman MS, West DP, Hirschfeld S, Grillo-Lopez AJ, Bennett CL.

J Clin Oncol. 2009 Sep 10;27(26):4398-405. Epub 2009 Jul 27.PMID: 19636013 [PubMed - indexed for MEDLINE]Related articles

The COMPARE Registry: Design and Baseline Patterns of Care for Men With Biochemical Failure After Definitive Treatment of Localized Prostate Cancer.

Sartor O, McLeod DG, Halabi S, Schellhammer PF, Scardino PT, D'Amico AV, Bennett C, Wei JT; COMPARE Registry Steering Committee.

Urology. 2009 Jul 7. [Epub ahead of print]PMID: 19589569 [PubMed - as supplied by publisher]Related articles

Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate.

Dorr DA, Burdon R, West DP, Lagman J, Georgopoulos C, Belknap SM, McKoy JM, Djulbegovic B, Edwards BJ, Weitzman SA, Boyle S, Tallman MS, Talpaz M, Sartor O, Bennett CL.

Clin Cancer Res. 2009 Jun 1;15(11):3850-5. Epub 2009 May 19.PMID: 19458059 [PubMed - indexed for MEDLINE]Related articles

Evaluation of 8q24 and 17q risk loci and prostate cancer mortality.

Penney KL, Salinas CA, Pomerantz M, Schumacher FR, Beckwith CA, Lee GS, Oh WK, Sartor O, Ostrander EA, Kurth T, Ma J, Mucci L, Stanford JL, Kantoff PW, Hunter DJ, Stampfer MJ, Freedman ML.

Clin Cancer Res. 2009 May 1;15(9):3223-30. Epub 2009 Apr 14.PMID: 19366828 [PubMed - indexed for MEDLINE]Related articles

Radiopharmaceutical and chemotherapy combinations in metastatic castrate-resistant prostate cancer: a new beginning?

Sartor O.

J Clin Oncol. 2009 May 20;27(15):2417-8. Epub 2009 Apr 13. No abstract available. PMID: 19364953 [PubMed - indexed for MEDLINE]Related articles

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL.

Blood. 2009 May 14;113(20):4834-40. Epub 2009 Mar 5.PMID: 19264918 [PubMed - indexed for MEDLINE]Related articles

Solitary adrenal metastatic lesion in a patient with a history of prostate cancer.

Barrisford GW, Sartor O, Richie JP.

Clin Genitourin Cancer. 2009 Jan;7(1):64-6.PMID: 19213672 [PubMed - indexed for MEDLINE]Related articles

A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.

Figg WD, Hussain MH, Gulley JL, Arlen PM, Aragon-Ching JB, Petrylak DP, Higano CS, Steinberg SM, Chatta GS, Parnes H, Wright JJ, Sartor O, Dahut WL.

J Urol. 2009 Mar;181(3):1104-13; discussion 1113. Epub 2009 Jan 23.PMID: 19167733 [PubMed - indexed for MEDLINE]Related articles

Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.

Choueiri TK, Xie W, D'Amico AV, Ross RW, Hu JC, Pomerantz M, Regan MM, Taplin ME, Kantoff PW, Sartor O, Oh WK.

Cancer. 2009 Mar 1;115(5):981-7.PMID: 19152438 [PubMed - indexed for MEDLINE]Related articles

Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy.

Shah SK, Trump DL, Sartor O, Tan W, Wilding GE, Mohler JL.

J Urol. 2009 Feb;181(2):621-6. Epub 2008 Dec 16.PMID: 19091347 [PubMed - indexed for MEDLINE]Related articles

Highlights from: The 2008 meeting of the American Society of Clinical Oncology; May 30-June 3, 2008; Chicago, IL.

Grothey E, Gibson T, Sartor O, Bukowski R.

Clin Genitourin Cancer. 2008 Sep;6(2):65-72. No abstract available. PMID: 18824427 [PubMed - indexed for MEDLINE]Related articlesFree article

Decision-making in clinically localized prostate cancer: evaluating and communicating risks.

Sartor O.

Clin Genitourin Cancer. 2008 Sep;6(2):63-4. No abstract available. PMID: 18824426 [PubMed - indexed for MEDLINE]Related articlesFree article

Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.

Gulley JL, Aragon-Ching JB, Steinberg SM, Hussain MH, Sartor O, Higano CS, Petrylak DP, Chatta GS, Arlen PM, Figg WD, Dahut WL.

J Urol. 2008 Oct;180(4):1432-7; discussion 1437. Epub 2008 Aug 16.PMID: 18710748 [PubMed - indexed for MEDLINE]Related articlesFree article

Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies.

Sartor O.

J La State Med Soc. 2008 Mar-Apr;160(2):99-100.PMID: 18681353 [PubMed - indexed for MEDLINE]Related articles

Substantial activity of mitoxantrone and paclitaxel in a heavily pre-treated metastatic bladder cancer patient.

Schmeeckle KD, Kim JW, Sartor O.

J La State Med Soc. 2008 Jan-Feb;160(1):17-8.PMID: 18669404 [PubMed - indexed for MEDLINE]Related articles

Increased uptake of 18F-fluorodeoxyglucose due to Mycobacterium avium complex in a solitary pulmonary nodule.

Schmeeckle KD, Yankelevitz D, Kim JW, Sartor O.

J La State Med Soc. 2008 May-Jun;160(3):150-2.PMID: 18655652 [PubMed - indexed for MEDLINE]Related articles

Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to bone.

Higano CS, Quick DP, Bushnell D, Sartor O.

Clin Genitourin Cancer. 2008 Mar;6(1):40-5.PMID: 18501082 [PubMed - indexed for MEDLINE]Related articles

Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time.

Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O; Prostate Specific Antigen Working Group.

J Urol. 2008 Jun;179(6):2181-5; discussion 2185-6. Epub 2008 Apr 18.PMID: 18423743 [PubMed - indexed for MEDLINE]Related articlesFree article

Second-line chemotherapy for advanced hormone-refractory prostate cancer.

Garmey EG, Sartor O, Halabi S, Vogelzang NJ.

Clin Adv Hematol Oncol. 2008 Feb;6(2):118-22, 127-32. Review.PMID: 18347563 [PubMed - indexed for MEDLINE]Related articles

Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes.

Bao BY, Chuang BF, Wang Q, Sartor O, Balk SP, Brown M, Kantoff PW, Lee GS.

Prostate. 2008 Jun 1;68(8):839-48.PMID: 18302198 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.

Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK.

Cancer. 2008 Mar 15;112(6):1247-53.PMID: 18293426 [PubMed - indexed for MEDLINE]Related articlesFree article

Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.

Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin ME, Regan MM, Kantoff PW, Freedman M.

J Clin Oncol. 2008 Feb 20;26(6):842-7.PMID: 18281655 [PubMed - indexed for MEDLINE]Related articles

Survival analyses overview in hormone-refractory prostate cancer clinical trials in the prostate-specific antigen era.

Sartor O.

Clin Genitourin Cancer. 2007 Dec;5(7):420-1. No abstract available. PMID: 18272022 [PubMed - indexed for MEDLINE]Related articles

Recruitment strategies and comparison of prostate cancer-specific clinical data on African-American and Caucasian males with and without family history.

Mandal DM, Sartor O, Halton SL, Mercante DE, Bailey-Wilson JE, Rayford W.

Prostate Cancer Prostatic Dis. 2008;11(3):274-9. Epub 2008 Feb 12.PMID: 18268528 [PubMed - indexed for MEDLINE]Related articlesFree article

Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.

Nakabayashi M, Sartor O, Jacobus S, Regan MM, McKearn D, Ross RW, Kantoff PW, Taplin ME, Oh WK.

BJU Int. 2008 Feb;101(3):308-12.PMID: 18184327 [PubMed - indexed for MEDLINE]Related articles

Interactions of cytokine gene polymorphisms in prostate cancer risk.

Zabaleta J, Lin HY, Sierra RA, Hall MC, Clark PE, Sartor OA, Hu JJ, Ochoa AC.

Carcinogenesis. 2008 Mar;29(3):573-8. Epub 2008 Jan 3.PMID: 18174250 [PubMed - indexed for MEDLINE]Related articlesFree article

Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.

Eggener SE, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O, Hricak H, Wheeler TM, Fine SW, Trachtenberg J, Rubin MA, Ohori M, Kuroiwa K, Rossignol M, Abenhaim L; International Task Force on Prostate Cancer and the Focal Lesion Paradigm.

J Urol. 2007 Dec;178(6):2260-7. Epub 2007 Oct 15. Review.PMID: 17936815 [PubMed - indexed for MEDLINE]Related articles

Chemotherapy in prostate cancer: an update.

Sartor O.

Clin Genitourin Cancer. 2007 Jun;5(5):304-5. No abstract available. PMID: 17645826 [PubMed - indexed for MEDLINE]Related articles

cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis.

Wu D, Zhau HE, Huang WC, Iqbal S, Habib FK, Sartor O, Cvitanovic L, Marshall FF, Xu Z, Chung LW.

Oncogene. 2007 Aug 2;26(35):5070-7. Epub 2007 Feb 19.PMID: 17310988 [PubMed - indexed for MEDLINE]Related articles

Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain.

Sartor O, Reid RH, Bushnell DL, Quick DP, Ell PJ.

Cancer. 2007 Feb 1;109(3):637-43.PMID: 17167764 [PubMed - indexed for MEDLINE]Related articlesFree article

Assessing progress against prostate cancer.

Sartor O, Alchalabi T, Figg WD.

Clin Genitourin Cancer. 2006 Sep;5(2):102-3. No abstract available. PMID: 17026796 [PubMed - indexed for MEDLINE]Related articles

Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease.

Sartor O.

Rev Urol. 2004;6 Suppl 10:S3-S12.PMID: 16985930 [PubMed - in process]Related articlesFree article

The emotional burden of low-risk prostate cancer: proposal for a change in nomenclature.

Sartor O, Loriaux DL.

Clin Genitourin Cancer. 2006 Jun;5(1):16-7. No abstract available. PMID: 16859573 [PubMed - indexed for MEDLINE]Related articles

The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel.

Saad F, Higano CS, Sartor O, Colombel M, Murray R, Mason MD, Tubaro A, Schulman C.

Clin Genitourin Cancer. 2006 Mar;4(4):257-62. Review.PMID: 16729908 [PubMed - indexed for MEDLINE]Related articles

The continuing challenge of hormone-refractory prostate cancer.

Sartor O.

Clin Genitourin Cancer. 2006 Mar;4(4):238-9. No abstract available. PMID: 16729904 [PubMed - indexed for MEDLINE]Related articles

A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer.

Crawford ED, Sartor O, Chu F, Perez R, Karlin G, Garrett JS.

J Urol. 2006 Feb;175(2):533-6.PMID: 16406989 [PubMed - indexed for MEDLINE]Related articles

Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugs.

McKoy JM, Lyons EA, Obadina E, Carson K, Pickard AS, Schellhammer P, McLeod D, Boyd CE, McWilliams N, Sartor O, Schumock GT, McCaffery K, Bennett CL.

J Clin Oncol. 2005 Dec 1;23(34):8894-905. Review.PMID: 16314650 [PubMed - indexed for MEDLINE]Related articles

Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.

Nakabayashi M, Regan MM, Lifsey D, Kantoff PW, Taplin ME, Sartor O, Oh WK.

BJU Int. 2005 Oct;96(6):783-6.PMID: 16153200 [PubMed - indexed for MEDLINE]Related articles

Amplification and overexpression of prosaposin in prostate cancer.

Koochekpour S, Zhuang YJ, Beroukhim R, Hsieh CL, Hofer MD, Zhau HE, Hiraiwa M, Pattan DY, Ware JL, Luftig RB, Sandhoff K, Sawyers CL, Pienta KJ, Rubin MA, Vessella RL, Sellers WR, Sartor O.

Genes Chromosomes Cancer. 2005 Dec;44(4):351-64.PMID: 16080200 [PubMed - indexed for MEDLINE]Related articles

Prostate-specific antigen endpoints in hormone-refractory prostate cancer.

Sartor O, George D.

Clin Prostate Cancer. 2005 Jun;4(1):5-6. No abstract available. PMID: 15992455 [PubMed - indexed for MEDLINE]Related articles

Relationships between reverse transcriptase-polymerase chain reaction for prostate specific antigen, survival, and various prognostic laboratory factors in patients with hormone refractory prostate cancer.

Gandhok NK, Looney S, Koochekpour S, Sartor O.

Urol Oncol. 2005 May-Jun;23(3):163-7.PMID: 15907715 [PubMed - indexed for MEDLINE]Related articles

Saposin C stimulates growth and invasion, activates p42/44 and SAPK/JNK signaling pathways of MAPK and upregulates uPA/uPAR expression in prostate cancer and stromal cells.

Koochekpour S, Sartor O, Hiraiwa M, Lee TJ, Rayford W, Remmel N, Sandhoff K, Minokadeh A, Patten DY.

Asian J Androl. 2005 Jun;7(2):147-58.PMID: 15897971 [PubMed - indexed for MEDLINE]Related articlesFree article

Role of 5a-reductase inhibitors and selective estrogen receptor modulators as potential chemopreventive agents for prostate cancer.

Price N, Sartor O, Hutson T, Mariani S.

Clin Prostate Cancer. 2005 Mar;3(4):211-4. No abstract available. PMID: 15882476 [PubMed - indexed for MEDLINE]Related articles

Highlights from the 2005 American Society of Clinical Oncology Prostate Cancer Symposium, Orlando, Florida.

Reddy GK, Gibson TB, Hutson T, Marianni S, Sartor O.

Clin Prostate Cancer. 2005 Mar;3(4):206-10. No abstract available. PMID: 15882475 [PubMed - indexed for MEDLINE]Related articles

Is there a role for less invasive therapeutic approaches for low- and intermediate-grade organ-confined prostate cancer?

Sartor O.

Clin Prostate Cancer. 2005 Mar;3(4):205. No abstract available. PMID: 15882474 [PubMed - indexed for MEDLINE]Related articles